Pharmaceutical United Biotechnology Co., Ltd. (WuXi XDC Cayman Inc.) filed an updated Securities Change Month Report with Hong Kong Trading and Settlement Limited on April 5, 2024, reporting the changes in the company's shares for the year ended March 31, 2024. The report showed that the company's regulated/registered capital reserves remained at 10,000,000,000 shares with a face value of $0.00005 per share for a total of $500,000, with no increase or decrease this month. In addition, under the share option plan for 2021 and 2023, the Company has detailed the grant date, exercise price and date of approval of the General Meeting of Shareholders for each period, and confirms that no new shares will be issued during this month as a result of the exercise of the share options. The report also notes that the Company has complied with all relevant legal requirements and confirms that all securities issued have received formal authorization from the Board of Directors.

Pharmaceutical United Biotechnology Co., Ltd. (WuXi XDC Cayman Inc.) filed an updated Securities Change Month Report with Hong Kong Trading and Settlement Limited on April 5, 2024, reporting the changes in the company's shares for the year ended March 31, 2024. The report showed that the company's regulated/registered capital reserves remained at 10,000,000,000 shares with a face value of $0.00005 per share for a total of $500,000, with no increase or decrease this month. In addition, under the share option plan for 2021 and 2023, the Company has detailed the grant date, exercise price and date of approval of the General Meeting of Shareholders for each period, and confirms that no new shares will be issued during this month as a result of the exercise of the share options. The report also notes that the Company has complied with all relevant legal requirements and confirms that all securities issued have received formal authorization from the Board of Directors.